ReachMD

Be part of the knowledge.™

Oncology and Hematology

184

LikeLikedUnlike

Episodes 16-30 of 273

The Latest Insights into Rare Blood Disorders: Diagnosis and Treatment Strategies
CME/CE
The Latest Insights into Rare Blood Disorders: Diagnosis and Treatment Strategies
- David J. Kuter, MD, DPhil
  Peer
- Spero R. Cataland, MD
  Peer
- Catherine Broome, MD
  Peer
- Cindy Neunert, MD, MSCS
  Peer
1.00 credits
Unlocking the Potential of HER3-Targeted Therapy: Breakthroughs in EGFR-Mutant NSCLC Therapeutic Approaches
CME/CE
Unlocking the Potential of HER3-Targeted Therapy: Breakthroughs in EGFR-Mutant NSCLC Therapeutic Approaches
- Jyoti Patel, MD
  Peer
- Pasi Antero Jänne, MD, PhD
  Peer
0.50 credits
Unlocking the Potential of TROP2-Targeted Therapy: Breakthroughs in NSCLC Therapeutic Approaches
CME/CE
Unlocking the Potential of TROP2-Targeted Therapy: Breakthroughs in NSCLC Therapeutic Approaches
- Benjamin Levy, MD
  Peer
- Alexander Spira, MD, PhD, FACP
  Peer
0.25 credits
A Roadmap to Safe and Effective Bispecific Antibody Use in Myeloma: Mitigating and Managing Adverse Events
CME/CE
A Roadmap to Safe and Effective Bispecific Antibody Use in Myeloma: Mitigating and Managing Adverse Events
- Caitlin Costello, MD
  Peer
- Sagar Lonial, MD, FACP
  Peer
0.25 credits
Unlocking the Potential of HER2-Targeted Therapy: Breakthroughs in NSCLC Therapeutic Approaches
CME/CE
Unlocking the Potential of HER2-Targeted Therapy: Breakthroughs in NSCLC Therapeutic Approaches
- Helena Yu, MD
  Peer
0.25 credits
Integrating Bispecific Antibodies Into Clinical Practice
MinuteCE®
Integrating Bispecific Antibodies Into Clinical Practice
- Sagar Lonial, MD, FACP
  Peer
- Caitlin Costello, MD
  Peer
1.00 program credits
Intracranial Activity of ROS1 TKIs
MinuteCE®
Intracranial Activity of ROS1 TKIs
- Charu Aggarwal, MD, MPH
  Peer
1.00 program credits
Treatment Strategy of ROS1-Rearranged NSCLC in TKI-Naive Patient
MinuteCE®
Treatment Strategy of ROS1-Rearranged NSCLC in TKI-Naive Patient
- Charu Aggarwal, MD, MPH
  Peer
- Alexander Drilon, MD
  Peer
1.00 program credits
Overcoming Acquired TKI-Resistance with Next-generation ROS1-TKI Agents
MinuteCE®
Overcoming Acquired TKI-Resistance with Next-generation ROS1-TKI Agents
- Charu Aggarwal, MD, MPH
  Peer
- Alexander Drilon, MD
  Peer
1.00 program credits
Preventing CRS and Neurotoxicities Related to Bispecific Antibodies
MinuteCE®
Preventing CRS and Neurotoxicities Related to Bispecific Antibodies
- Sagar Lonial, MD, FACP
  Peer
- Caitlin Costello, MD
  Peer
1.00 program credits
Bispecific Antibodies: The Newest Immunotherapy on the Block for RRMM
MinuteCE®
Bispecific Antibodies: The Newest Immunotherapy on the Block for RRMM
- Sagar Lonial, MD, FACP
  Peer
- Caitlin Costello, MD
  Peer
1.00 program credits
Managing Infections, Cytopenias, and Other AEs Related to Bispecific Antibodies
MinuteCE®
Managing Infections, Cytopenias, and Other AEs Related to Bispecific Antibodies
- Sagar Lonial, MD, FACP
  Peer
- Caitlin Costello, MD
  Peer
1.00 program credits
Current Guidelines and Real-World Evidence for ROS1 Testing in NSCLC
MinuteCE®
Current Guidelines and Real-World Evidence for ROS1 Testing in NSCLC
- Charu Aggarwal, MD, MPH
  Peer
1.00 program credits
Considerations for Dosing Bispecific Antibodies
MinuteCE®
Considerations for Dosing Bispecific Antibodies
- Sagar Lonial, MD, FACP
  Peer
- Caitlin Costello, MD
  Peer
1.00 program credits
Later-Line Targeted Therapies for ROS1 Fusion-Positive Lung Cancers
MinuteCE®
Later-Line Targeted Therapies for ROS1 Fusion-Positive Lung Cancers
- Alexander Drilon, MD
  Peer
1.00 program credits

Program Chapters

Segment Chapters

Playlist:

Recommended